Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo significantly improved PFS and OS in colorectal cancer with BRAF ...

Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

BRAFTOVI's FDA Approval Sparks Hope for BRAF V600E-mutant Colorectal Cancer Patients and Sets Pfizer Up for Explosive Growth ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...